EyePoint Pharmaceuticals Inc (STU:PV3B)
€ 7.012 0.01 (0.14%) Market Cap: 382.82 Mil Enterprise Value: 152.78 Mil PE Ratio: 0 PB Ratio: 1.83 GF Score: 59/100

Q3 2023 EyePoint Pharmaceuticals Inc Earnings Call Transcript

Nov 01, 2023 / 12:30PM GMT
Release Date Price: €6.15 (+10.81%)
Operator

Good morning. My name is Liway, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Third Quarter 2023 Financial Results and Recent Corporate Development Conference Call. There will be a question-and-answer session to follow at the completion of the prepared remarks. Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to George Elston, Executive Vice President and Chief Financial Officer of the EyePoint Pharmaceuticals. Please go ahead.

George O. Elston
EyePoint Pharmaceuticals, Inc. - Executive VP & CFO

Thank you, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' third quarter 2023 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer. Jay will begin with a review of recent corporate updates and discuss the ongoing Phase II clinical trials for EYP-1901. I will close with commentary on the third

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot